Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Produ
100 November Sustainable Dividend Dogs: 50 'Safer' And 2 Ideal Buys
06:54pm, Thursday, 14'th Nov 2024
Calvert Research and Management ranked the 100 most sustainable companies based on over 230 ESG indicators, including workplace diversity and greenhouse-gas emissions. Eight of 78 dividend-paying sust
Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
09:17am, Thursday, 14'th Nov 2024
Merck's stock is undervalued, trading at less than 4x expected 2024 revenues, despite strong revenue growth from Keytruda and other drugs. Keytruda's revenue is projected to increase by 70% from 2024
Merck to Participate in the Jefferies London Healthcare Conference
07:15am, Thursday, 14'th Nov 2024
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies London Healthcare Conference.
Merck signs $3.3 bln deal for experimental cancer drug
07:02am, Thursday, 14'th Nov 2024
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
06:45am, Thursday, 14'th Nov 2024
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today
Merck & Co., Inc. (MRK) UBS Global Healthcare Conference (Transcript)
04:03pm, Wednesday, 13'th Nov 2024
Merck & Co., Inc. (NYSE:MRK ) UBS Global Healthcare Conference November 13, 2024 12:30 PM ET Company Participants Jannie Oosthuizen - President of Human Health of the U.S. Joerg Koglin - SVP of Clinic
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KOSELUGO Showed Significant and Clinically Meaningful Improvement in ORR Versus Placebo in Adults With NF1 who Have Symptomatic, Inoperable PNs.
5 Relatively Secure And Cheap Dividend Stocks - November 2024: Yields Up To 9%
09:00am, Saturday, 09'th Nov 2024
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering pr
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
10:05am, Friday, 08'th Nov 2024
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
07:00am, Friday, 08'th Nov 2024
If you're patient, these businesses have a lot of promising projects in the works.
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
09:05am, Thursday, 07'th Nov 2024
These stocks have seen better days but investors shouldn't count them out in the long run.
Merck: An Undervalued Dividend Machine
08:51am, Thursday, 07'th Nov 2024
Keytruda, Merck's flagship oncology drug, drives significant revenue growth, with a solid market position and patent protection ensuring continued growth. Merck is the second largest player in the onc
Is MRK Stock Undervalued At $100?
01:49am, Thursday, 07'th Nov 2024
Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It garnered $16.7 billion in revenue and adjusted earnings of $1.57 per share, compared t
Merck to Participate in the UBS Global Healthcare Conference
06:45am, Wednesday, 06'th Nov 2024
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the UBS Global Healthcare Conference.
